Pfizer Canada was pleased to welcome Manitoba Conservative MPs Raquel Dancho (Kildonan—St. Paul), and Grant Jackson (Brandon-Souris) at our manufacturing facility in Brandon, Manitoba. We are proud of Pfizer’s long history in Brandon and the role that Pfizer has in supporting patients, Manitoba’s equine and agricultural communities, and economic contributions across Canada. We appreciated the opportunity to discuss the importance of a strong innovative life sciences sector in Canada.
About us
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
- Website
-
https://www.pfizer.com/?source=Linkedin
External link for Pfizer
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- New York, New York
- Type
- Public Company
- Specialties
- To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them.
Locations
Employees at Pfizer
Updates
-
Pfizer reposted this
AI adoption is one thing, transformation is something else entirely. Few companies have been bold enough to fundamentally change how they are organized and how decisions are made. At Pfizer, we are determined to break through that inertia and be the most AI-forward company in our industry because of what this technology will do for patients. In R&D, as I said on our earnings call this week, our ambition is to build an AI-native organization where every insight, from target discovery through medical evidence, continuously informs the next decision. We are making great progress, so I'd like to share more about how we think about it overall: why our 177 years of data is our alpha, why I chose a federated model over a central team, and why we are certifying every eligible colleague, including me, in AI fluency.
-
Halfway through 2026, and Pfizer R&D continues to execute with focus and discipline. Across Oncology, Internal Medicine, Vaccines and Inflammation & Immunology, we advanced critical R&D milestones: achieving approvals, pivotal data readouts, and new study starts. A diverse, deep pipeline, moving forward with purpose. Behind every milestone are years of rigorous science and the relentless work of our teams around the world. It's disciplined execution, sustained across every program and every team, that will keep our pipeline delivering quarter after quarter. Thank you to the Pfizer R&D teams and partners worldwide who are making this happen — every day, for patients everywhere.
-
Our second quarter results are out today, and I am proud to report another strong quarter of execution. Pfizer's commercial teams showed once again why we are leaders in this industry. Our R&D organization rose to the challenge of an ambitious 2026 plan, with three regulatory approvals, six key data readouts and eight pivotal study starts already achieved. And AI is changing how we work as well, in our laboratories, in our manufacturing plants and in the decisions we make every day. We can accomplish even more for patients, and I am excited about the opportunities ahead in oncology, obesity, vaccines and immunology, where the science is finally catching up to our ambition. Thank you to my colleagues, all of you, for everything behind these results and for your commitment to our purpose. You make me confident in Pfizer's future.
-
Pfizer reposted this
Only in America could a scientist from Greece rise to lead one of the world's great scientific companies. I have never taken that for granted, and I think about it even more as America turns 250. This country has always had a gift for making bold bets that changed the world. The moon landing, the internet, the Human Genome Project. These milestones and so many others came from generations of Americans who chose to invest in science and a belief in a brighter future. Today, America faces a choice once again. New tools in biology, from how we design medicines to how we manufacture them, have already expanded what is possible for patients. AI will shape what comes next in ways we are only beginning to see. Tools alone don’t determine outcomes. It requires investing in innovation. It requires committing to shaping future opportunities. The coming decade will determine where great new discoveries occur and where the most ambitious scientists build their life's work. I want the answer to be here. Other nations have serious scientific ambition, and I welcome it. Competition never scared America. It has always made us better. You don’t win races by trying to hold others back. You win by running faster, running harder. America’s opportunity is to continue leading by investing more, building more and moving faster. Pfizer will continue doing its part. We were founded in New York in 1849, and we have been competing and betting on American science ever since. We are driven by a single purpose: delivering breakthroughs that change patients' lives. My wish for America's 250th birthday is simple. Let us choose, once again, to bet on ourselves – and on science. No nation has ever done it better. #A250
-
-
Our Chief Scientific Officer, Chris Boshoff, MD, PhD, FMedSci, sat down with Scientific American to reflect on the state of American science and why he's optimistic about what's ahead. https://lnkd.in/dSg3R6q6
The convergence of biology, genomics, data science, and engineering is driving a new age of discovery that would have been unimaginable even a decade ago. My advice for early-career scientists: stay curious about biology and learn from failure. Techniques will change, but a deep grasp of disease mechanisms will remain essential. That conviction — about what endures and why it matters — is what I brought to a conversation with Scientific American for their "The Young American Scientists" series: where American science stands right now, what gives me optimism, and what I think we need to protect. Read here: https://lnkd.in/e26-cuRY Next week, America turns 250 — and at its best, this country has always been a story of restless curiosity, the freedom to ask hard questions and refuse easy answers. We saw that spirit alive again in the extraordinary public response to Artemis II: people didn't just notice, they felt it, because humans are wired to respond to audacious ambition. Sustained investment in foundational research is how civilizations turn curiosity into destiny. And scientists have a role too: not just in the laboratory, but in telling the story of why the work matters, in language that invites everyone in. The next 250 years belong to the questions we have the courage to ask today. #Science #Research #Pfizer
-
-
Pfizer is advancing our commitment to deliver transformative medicines for people living with cancer through a new strategic global collaboration with Innovent Biologics. Together, we will work to accelerate the research and development of 12 potentially promising early-stage and 𝑑𝑒 𝑛𝑜𝑣𝑜 oncology programs spanning antibody-drug conjugates (ADCs) and multi-specific antibodies with differentiated designs and novel mechanisms. By combining Pfizer Oncology’s global development, regulatory and commercial expertise with Innovent’s scientific discovery and early clinical capabilities, we aim to accelerate the delivery of next-generation breakthroughs for patients in the U.S. and around the world. This collaboration strengthens Pfizer’s Oncology pipeline and supports our long-term ambition to redefine standards of care and help address areas of significant unmet need in cancer treatment. https://lnkd.in/dXdvQ2cc #Pfizer #Oncology #CancerResearch #Biotech #Innovation
-
Pfizer reposted this
2026 is a pivotal year for Pfizer R&D, and I’m pleased with the strong progress we made this quarter. Across Oncology, metabolic disease, and vaccines — regulatory decisions, key data readouts, and new study starts. A pipeline advancing with focus and with purpose. Each milestone is the result of years of rigorous science and the relentless commitment of our teams worldwide. AI is becoming embedded in the fabric of R&D at Pfizer — helping accelerate discovery, sharpen decisions, and unlock insights from data at a scale and speed that would have been unimaginable just a few years ago. The future of medicine will be built at this intersection of bold science and intelligent technology. Thank you to the Pfizer R&D teams and partners worldwide who are making this happen — every day, for patients everywhere. The best is ahead.
-
Pfizer began 2026 with focus, confidence, and an unwavering commitment to patients. As we report our first quarter earnings, that commitment remains stronger than ever — driving us to deliver breakthroughs that change patients' lives today and into the future.
Pfizer started 2026 with focus and speed. Our first quarter results reflect what this team can deliver when we are aligned on what matters: strong commercial performance, meaningful pipeline progress, AI accelerating how we work across the organization and more. Every day we move faster is a day a patient gets an answer sooner. I am grateful to my colleagues for the remarkable work behind these results, and for remaining clear-eyed about our purpose. Read more: https://lnkd.in/emy9sT3D
-
When treating cancer, time is critical. That’s what makes the use of AI in oncology so pivotal. Today, AI is helping researchers identify potential clinical trial participants earlier, before critical windows close. The goal: more patients gaining access to investigational therapies and accelerated drug discovery. Discover how AI is already reshaping cancer research: https://lnkd.in/eytQhGVd #AIinHealthcare #OncologyResearch #ClinicalTrials #InnovationInMedicine #Biopharma #HealthTech #PatientAccess
-